Cardurion Pharmaceuticals
Last verified 2026-05-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $260.0Mattributed |
|---|---|
| Latest round | series-b, $260.0M, 2024-07-01attributed |
| Founded | unknown |
| Headquarters | Burlington MA |
| Industry | biotech|cardiovascular|therapeutics |
| Stage | series-b+ |
| Website | cardurion.com |
Cardurion Pharmaceuticals develops cardiovascular treatments centered on PDE9 inhibition for heart failure and CaMKII inhibition for arrhythmias and rare heart conditions. It targets patients with chronic heart failure and rare genetic diseases like CPVT who lack adequate therapies today. The company is the first to advance a CaMKII inhibitor through clinical studies, opening multiple cardiac indications around the mechanism.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-07-01 | series-b | $260.0M | undisclosed |
Detected tech stack
Cloudflare, WordPress, Yoast SEO 27.4, Google Tag Manager, Gravity Forms 2.10.2, jQuery Migrate 3.4.1, imagesLoaded 5.0.0, Elementor 4.0.3, Essential Addons for Elementor, Cloudflare Bot Management, ZURB Foundation, WP Engine
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $260.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $260.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | cardurion.com, read 2026-05-05 |
| Description | self-reported | cardurion.com, read 2026-05-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.